Cutera (CUTR) investor relations material

Executive summary

• Q3 2024 revenue was $32.5 million, down 30% year-over-year, mainly due to lower system sales, macroeconomic headwinds, and the end of a skincare distribution agreement.

• AviClear revenue grew 16% year-over-year, driven by international expansion and strong capital system sales outside North America.

• Gross margin declined to 5.6% in Q3 2024 from 13.9% a year ago, mainly due to a $10.1 million non-cash inventory charge and lower manufacturing activity.

• The company ended the quarter with $59.0 million in cash, cash equivalents, and restricted cash, down from $84.3 million at June 2024 and $143.6 million at year-end 2023.

• Substantial doubt exists about the company’s ability to continue as a going concern over the next year.

Financial highlights

• Q3 2024 total revenue was $32.5 million, down from $46.5 million in Q3 2023; nine-month revenue was $105.7 million, down 35% year-over-year.

• Q3 2024 net loss was $39.0 million ($1.94 per share); nine months: $86.5 million.

• Non-GAAP gross profit was $3.7 million (11.5% margin), down from 19.3% in Q3 2023, mainly due to a $10.1 million inventory charge.

• Operating expenses for Q3 2024 were $38.0 million (GAAP), with non-GAAP operating expenses at $34.7 million, reflecting cost reductions and a $5.4 million bad debt charge.

• Cash used in operations for nine months was $82.6 million.

Outlook and guidance

• Full-year 2024 revenue guidance reaffirmed at $140 million–$145 million.

• Year-end 2024 cash, cash equivalents, and restricted cash expected to be approximately $40 million.

• Anticipates over 50% reduction in cash burn in 2025, mainly from working capital improvements, even without revenue growth.

• Management expects continued losses and negative cash flow, with ongoing cost-saving initiatives and a focus on transitioning AviClear to a direct sales model.

• The company is evaluating additional funding options and may need to raise capital to support operations.